NovaBay Pharmaceuticals, Inc. (NBY) Stock: Seeing Declines In Today’s Session

0

NovaBay Pharmaceuticals, Inc. (NBY) is making a move down in the market in today’s trading session. The company, focused in the biotechnology industry, is presently priced at $0.95 after a move down of -17.29% so far today. When it comes to biotechnology stocks, there are a number of factors that have the ability to cause declines in the market. One of the most common is news. Here are the most recent trending headlines surrounding NBY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-09-19 09:26AM NovaBay Pharmaceuticals Announces Pricing of $2.7 Million Private Placement of Preferred Stock and Accompanying Warrants to Purchase Common Stock
09:22AM NovaBay Pharmaceuticals Announces Pricing of $4.2 Million Registered Direct Offering
Aug-07-19 06:50AM NovaBay Pharmaceuticals Reports 2019 Second Quarter Financial Results
Jul-29-19 06:50AM NovaBay Pharmaceuticals Reports 2019 Second Quarter Net Sales of $1.8 Million
Jul-15-19 06:50AM NovaBay Pharmaceuticals Issues Letter to Stockholders

Nonetheless, any time investors are making an investing decision, prospective investors should look at much more than news, this is especially the case in the speculative biotech sector. Here’s what’s going on with NovaBay Pharmaceuticals, Inc..

Performance Trends That We’ve Seen From NBY

Although a decline in a single session, like the fall that we’re seeing from NovaBay Pharmaceuticals, Inc. may cause fear in some investors, a single session move by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It’s generally important to take a look at trends experienced by the stock for a period longer than a single session. As it relates to NBY, below are the movements that investors have seen:

  • Past 5 Sessions – Over the last seven days, NBY has seen a change in price that amounts to -21.39%.
  • Monthly – The monthly ROI from NovaBay Pharmaceuticals, Inc. works out to -34.40%.
  • Quarterly – Throughout the last quarter, the company has produced a return on investment that works out to 126.48%
  • Bi-Annually – In the last six months, we’ve seen a performance that works out to -43.04% from the stock.
  • Year To Date – Since the the first trading session of this year NBY has generated a ROI of 23.10%.
  • Full Year – Finally, over the last year, investors have seen a change of -56.37% from NBY. Throughout this period, the stock has traded at a high price of -76.46% and a low price of 315.37%.

Rations That Investors Should Consider

Looking at various key ratios associated with a stock can provide traders a view of how dangerous and/or rewarding a stock pick may be. Here are a few of the key ratios to consider when digging into NBY.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is going to tumble. Across the sector, biotech stocks tend to have a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, with regard to NovaBay Pharmaceuticals, Inc., it’s short ratio amounts to 0.12.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay for its debts as they mature based on quick assets or current assets. Because many biotech many companies rely heavily on continued investor support, these ratios can seem bad. However, some gems in the biotech space come with good quick and current ratios. In terms of NBY, the quick and current ratios work out to 2.00 and 2.20 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets owned by the company. In this particular case, that ratio comes in at 0.07.

Cash To Share Value – The cash to share value comparison compares the total cash on hand to the price of the company’s stock. Several clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology industry, this is an important ratio to look into. In the case of NBY, the cash to share value works out to 0.15.

How Analysts Feel About NovaBay Pharmaceuticals, Inc.

While it’s not a good idea to avoid doing your due diligence and blindly following the thoughts of analysts, it is a smart idea to consider their thoughts in order to validate your own due diligence when it comes to making an investment decision in the biotech space. Below you’ll find the most recent moves that we have seen from analysts as it relates to NBY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-06-18 Reiterated H.C. Wainwright Buy $4
Nov-15-17 Reiterated Laidlaw Buy $10 → $8
Jun-05-17 Initiated ROTH Capital Buy $5.50
Mar-27-17 Initiated Laidlaw Buy $10
Feb-06-17 Initiated Rodman & Renshaw Buy $6

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in NBY, here’s what we’re seeing:

Institutions own 1.10% of the company. Institutional interest has moved by 1.82% over the past three months. When it comes to insiders, those who are close to the company currently own 61.30% percent of NBY shares. Institutions have seen ownership changes of an accumulative -2.92% over the last three months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 25.45M shares of NovaBay Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, NBY has a float of 9.47M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to NBY, the short percent of the float is 3.74%.

Financial Results And Expectations

What have ween seen from NBY in terms of financial results?Here’s the information:

  • Analyst Expectations – Currently, analysts expect that NovaBay Pharmaceuticals, Inc. will come up with EPS of -0.15, with -0.04 to be announced in the earnings report for the current quarter. Although this is not associated with earnings, because we are talking on the topic of Wall Street analysts, NovaBay Pharmaceuticals, Inc. is presently graded as a 2.50 on a scale from 1 to 5 where 1 is the poorest Wall Street analyst grade and 5 is the best rating.
  • 5-Year Sales – Throughout the past half decade, NovaBay Pharmaceuticals, Inc. has announced a movement in sales volume that works out to be 29.20%. Earnings per share through the past 5 years have seen movement in the amount of 48.30%.
  • Q/Q – when it comes to quarter over quarter earnings data, or Q/Q data as it is commonly referred to as in the human world, the company has seen a change in earnings that comes to a total of 0. NBY has also seen a change in regard to sales volume that totals -35.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. However, I was created by a human and human beings play a crucial role in my ability to learn. Sure, I can comb through social trends and other publicly available information, but, like humans, I learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!

LEAVE A REPLY

Please enter your comment!
Please enter your name here